

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

RoM = robust average
 SD = standard deviation
 CV = coefficient of variation
 Ntot = total number of the participants
 Nout = number of results excluded before calculation

AV = assigned value
 CRV = certified reference value
 RV = reference value
 CVE = consensus value from experts
 CVP = consensus value from all participants
 CVPG = consensus value from participants groups
 U_{AV} = expanded uncertainty of the assigned value (k = 2)

Dmax = acceptable percent difference
 LL = lower limit
 UL = upper limit
 Neva = number of evaluated participants
 Nsuc = number of successful participants
 Srel = success (relative)

Test	[unit]	Comparability										Traceability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
Set 1																								
(81) Digoxin	[µg/L]				15							0								15	14	93%		
Samples and groups																								
Sample A1		0,967	0,22	23	15							0				CRV	1,032	,0100	36%	0,66	1,41	15	14	93%
(4) LIA, ILMA		0,988	0,39	39	8	0																8		
(6) Immunoturbidimetry, KIMS		1,01	0,01	1,5	5	0																5		
Other					2	0																2		
Sample B1		2,13	0,35	16	15							0				CRV	2,149	0,023	36%	1,37	2,93	15	15	100%
(4) LIA, ILMA		2,13	0,71	33	8	0																8		
(6) Immunoturbidimetry, KIMS		2,22	0,08	4,0	5	0																5		
Other					2	0																2		
(84) Phenobarbital	[mg/L]				6							6	5	83%								0		
Samples and groups																								
Sample A1		27,7	1,4	5,1	6	CVP	25,3	1,2	20%	20,2	30,4	6	5	83%								0		
Other					6	0																6		
Sample B1		9,75	0,70	7,2	6	CVP	9,08	0,42	20%	7,26	10,9	6	6	100%								0		
Other					6	0															6			
(85) Phenytoin	[mg/L]				2							2	1	50%								0		
Samples and groups																								
Sample A1		5,96	2,1	36	2	CVP	9,57	0,24	20%	7,65	11,5	2	1	50%								0		
Other					2	0															2			
Sample B1		6,34	2,5	39	2	CVP	3,95	0,14	20%	3,16	4,74	2	1	50%								0		
Other					2	0														2				
(86) Carbamazepin	[mg/L]				11							11	9	82%								0		
Samples and groups																								
Sample A1		9,69	1,6	16	11	CVP	10,1	0,27	20%	8,08	12,2	11	9	82%								0		
Other					11	0														11				
Sample B1		3,27	0,55	17	11	CVP	3,43	0,11	20%	2,74	4,12	11	10	91%								0		
Other					11	0													11					
(88) Valproic acid	[mg/L]				12							12	11	92%								0		
Samples and groups																								
Sample A1		34,7	5,1	15	12	CVP	35,3	0,84	20%	28,2	42,4	12	11	92%								0		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability							Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}									AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}			
(88) Valproic acid	[mg/L]				12										12	11	92%					0			
Samples and groups																									
Sample A1		34,7	5,1	15	12		CVP	35,3	0,84	20%	28,2	42,4			12	11	92%					0			
(6) Immunoturbidimetry, KIMS		34,2	2,8	8,2	5	0										5									
Other					7	0										7									
Sample B1		126	13	10	12		CVP	127	2,1	20%	101	153			12	12	100%					0			
(6) Immunoturbidimetry, KIMS		121	9,1	7,5	5	0										5									
Other					7	0										7									
							1x 1, 2x 2, 4x 4																		
(82) Theophylline	[mg/L]				4										0						4	4	100%		
Samples and groups																									
Sample A1		20,8	3,5	17	4										0			CRV	22,58	0,23	24%	17,1	28	4	
Other					4	0										4									
Sample B1		17,2	2,6	15	4										0			1x 2, 2x 4, 1x 6	CRV	18,39	0,18	24%	13,9	22,9	4
Other					4	0										4									
																	1x 2, 2x 4, 1x 6								
Set 2																									
(89) Amicacin	[mg/L]				4										4	3	75%					0			
Samples and groups																									
Sample A2		18,7	3,0	16	4		CVP	18,1	0,35	20%	14,4	21,8			4	4	100%					0			
Other					4	0									4										
Sample B2		30,8	8,0	26	4		CVP	29,8	0,54	20%	23,8	35,8			4	3	75%					0			
Other					4	0									4										
							3x 2, 1x 6																		
(90) Gentamicin	[mg/L]				12										12	12	100%					0			
Samples and groups																									
Sample A2		7,46	1,5	20	12										12	12	100%					0			
Other					12	0									12										
Sample B2		3,61	0,58	16	12										12	12	100%					0			
Other					12	0									12										
							1x 0, 1x 1, 3x 2, 4x 4, 2x 6, 1x 6/60																		
(93) Methotrexate	[μmol/L]				3										3	3	100%					0			
Samples and groups																									
Sample A2		3,16	0,35	11	3		CVP	3,21	0,25	30%	2,24	4,18			3	3	100%					0			
Other					3	0									3										
Sample B2		1,08	0,03	3,1	3		CVP	1,1	0,052	30%	0,77	1,43			3	3	100%					0			
Other					3	0									3										
							1x 2, 2x 4																		
(92) Vancomycin	[mg/L]				13										13	13	100%					0			
Samples and groups																									
Sample A2		11,2	0,74	6,6	13		CVP	11	0,24	28%	7,92	14,1			13	13	100%					0			
(4) LIA, ILMA		11,7	0,53	4,5	6	0									6										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(92) Vankomycin	[mg/L]				13							13	13	100%									0
Samples and groups																							
Sample A2		11,2	0,74	6,6	13	CVP	11	0,24	28%	7,92	14,1	13	13	100%									0
Other					7	0						7											
Sample B2		16,3	1,1	6,5	13	CVP	15,9	0,34	28%	11,4	20,4	13	13	100%									0
(4) LIA, ILMA		16,9	0,73	4,3	6	0						6											
Other					7	0	1x 1, 3x 2, 3x 6					7											

st_kn_np

End of report

Printed: 14.10.2022